ClinicalTrials.gg
CompletedNCT05834738ASSISTUpdated Jul 20, 2026Results posted

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

A Phase 2 interventional study of Atrasentan and Atrasentan in IgA Nephropathy and Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
10th of 14
54 · median 108
Started
2023
with 1 other
Phase 2
5 of 18
2 open now
Registered
7th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 7th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

Read the detailed description

Patients with biopsy-proven IgAN who were on a background SGLT2i and a maximally tolerated and stable dose of a renin-angiotensin system inhibitor (RASi) [such as angiotensin converting enzyme inhibitor (ACEi) or angiotensin-receptor antagonist (ARB)] as part of standard of care, were randomized to either sequence Atrasentan/Placebo or sequence Placebo/Atrasentan in which they received 0.75 mg atrasentan once daily during one period (period A), complete a 12-week washout period, and then received matching placebo during the other period (period B) as determined by the randomization schema.

Subjects who were not on background SGLT2i therapy would first undergo a run-in period of 8 weeks with an SGLT2i with a 24-hour total urine protein of > 0.85 grams/day at screening prior to the run-in period and have 24-hour total urine protein of > 0.5 grams/day at the end of the run-in period to be eligible for randomization.

Subjects remained on their maximally tolerated and stable dose of RASi and stable dose of SGLT2i therapies for the duration of the study following randomization.

The primary objective of the study was to evaluate the efficacy of atrasentan vs. placebo while on background therapy with SGLT2i.

03

Conditions studied

  • IgA Nephropathy
  • Immunoglobulin A Nephropathy

Keywords

  • Kidney Diseases
  • Kidney Disease, Chronic
  • Urologic Diseases
  • Glomerulonephritis
  • Glomerular Disease
  • Glomerulonephritis, IGA
  • Glomerulopathy
  • Immunoglobulin Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Legal adults (per local and country specifications) ≥ 18 years of age at the time of signing the form (ICF) prior to initiation of any study specific activities/procedures.
  • -proven IgA nephropathy.
  • Receiving a maximally tolerated and stable dose of a RASi for at least 12 weeks prior to screening. Investigator discretion should be used in determining maximally tolerated and optimized dose.
  • of at least 30 mL/min/1.73 m\^2 at screening based on the 2021 CKD-EPI equation.
  • Willing to agree to highly effective forms of , as specified in the protocol, throughout the study and for up to 1 month afterward. In , use of hormonal contraceptive agents must have been started at least 1 month prior to baseline.
  • Willing and able to provide informed consent and comply with all study requirements.
  • Inclusion Criteria for SGLT2i stable subjects

    • Receiving a stable dose of an SGLT2i for at least 8 weeks prior to screening
    • Must have a 24-hour urine protein of >0.5 grams/day.
  • Inclusion Criteria for Run-In Subjects

    • Must have a 24-hour total urine protein of >0.85 grams/day at screening
    • Willing to participate in an 8-week run-in period with an SGLT2i (per Investigator choice)
  • Additional Inclusion Criteria for Run-in Subjects at the end of Run-In

    • Must have completed the 8-week run-in period on a stable and well tolerated dose of an SGLT2i
    • Must have a 24-hour total urine protein of >0.5 grams/day confirmed at the Run-in Week 8 visit.
    • Must have an eGFR of ≥ 30 mL/min/1.73 m\^2 based on the CKD-EPI equation at their Run-in Week 8 visit.

Exclusion Criteria:

  • Current diagnosis with another chronic kidney disease, including diabetic kidney disease.
  • History of kidney transplantation or other organ transplantation.
  • Use of systemic medications, such as , for more than 2 weeks in the past 3 months.
  • Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator.
  • Known history of heart failure or prior hospital admissions for conditions relating to fluid overload that in the opinion of the Principal Investigator or Sponsor might confound the results of the study or pose additional risk to the participant by their participation in the study.
  • history of liver disease as assessed by the Investigator.
  • below 9 g/dL as measured by the Investigator or prior history of blood transfusion for anemia within the past 3 months.
  • within the past 5 years. Exceptions to this criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ.
  • For women, pregnancy, breast feeding, or intent to become pregnant during the study. and at least 1 month afterward.
  • For men, intent to father a child or donate sperm during the study.
  • Have received any agent or approved treatment for IgAN (other than a RAS inhibitor) including SGLT2i (except for subjects in the SGLT2i stable stratum) within 1 month (or 5 half-lives of the agent, whichever is longer) prior to Screening. If the investigational agent is a cytotoxic or immunosuppressive agent then this is 6 months.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Sequence Atrasentan/Placebo

    Once daily oral administration of 0.75 mg atrasentan for 12 weeks (Period A) followed by once daily oral administration of placebo for 24 weeks (Period B)

    Drug: Atrasentan · Drug: Placebo

  • Experimental
    Sequence Placebo/Atrasentan

    Once daily oral administration of placebo for 12 weeks (Period B) followed by once daily oral administration of 0.75 mg atrasentan for 24 weeks (Period A)

    Drug: Atrasentan · Drug: Placebo

Interventions

  • Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo

    Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627

  • Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet

    Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12

    Change in proteinuria from Baseline to Week 12 across both periods between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.

    Time frame: From Baseline to Week 12

Secondary outcomes

  1. Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2.

    Change in proteinuria from Baseline to Week 24 in Treatment Period 2 between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.

    Time frame: From Baseline to Week 24 of Treatment Period 2

  2. Number of Subjects With TEAE and TEAESI

    Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Adverse Events of Special Interest (TEAESI). Severity assessment of AEs was based on CTCAE (Common Terminology Criteria for Adverse Events).

    Time frame: From first dose of study treatment until end of study, up to 60 weeks

  3. Plasma Concentration of Atrasentan

    Blood samples were collected for the measurement of plasma concentrations of atrasentan.

    Time frame: Treatment Period 1: Pre-dose on Weeks 2, 6 and 12; Treatment Period 2: Pre-dose on Weeks 2, 6, 12 and 24

07

Results

Posted Jul 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneSequence Atrasentan/PlaceboSequence Placebo/Atrasentan
Started2727
Completed treatment period 12727
Completed washout period2727
Completed treatment period 22626
Intention-to-treat (itt) analysis set2727
Safety analysis set2727
Pharmacokinetic analysis set2627
Completed2627
Not completed10
Withdrew: Physician decision10

Outcome measures

PrimaryPercentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12

Change in proteinuria from Baseline to Week 12 across both periods between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.

Time frame:
From Baseline to Week 12
Reported as:
Geometric least squares mean · percentage change in UPCR
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12
percentage change in UPCRAtrasentanPlacebo
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12-30.7 (-38.5 to -21.9)-7.2 (-17.7 to 4.7)
Statistical analysis
  • Atrasentan vs Placebo · Mixed Models Analysis · p = 0.0006 (2-side p-value) · % mean treatment difference: -25.3 · 95% CI -36.8 to -11.7
SecondaryPercentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2.

Change in proteinuria from Baseline to Week 24 in Treatment Period 2 between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.

Time frame:
From Baseline to Week 24 of Treatment Period 2
Reported as:
Geometric least squares mean · percentage change in UPCR
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2.
percentage change in UPCRAtrasentan Period 2Placebo Period 2
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2.-27.0 (-41.0 to -9.8)-0.9 (-20.6 to 23.7)
Statistical analysis
  • Atrasentan Period 2 vs Placebo Period 2 · Mixed Models Analysis · p = 0.0499 (2-sided p-value) · % mean treatment difference: -26.4 · 95% CI -45.8 to -0.0
SecondaryNumber of Subjects With TEAE and TEAESI

Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Adverse Events of Special Interest (TEAESI). Severity assessment of AEs was based on CTCAE (Common Terminology Criteria for Adverse Events).

Time frame:
From first dose of study treatment until end of study, up to 60 weeks
Reported as:
Count of participants · Participants
Number of Subjects With TEAE and TEAESI
ParticipantsAtrasentan Period 1Placebo Period 1Placebo Period 2Atrasentan Period 2
Adverse events (AEs)19171716
Treatment-related AEs6432
Any Moderate or Severe AEs7777
Treatment-related Moderate or Severe AEs1001
Severe AEs0001
Treatment-related Severe AEs0000
SAEs0001
Treatment-related SAEs0000
Adverse events of special interest6264
Treatment-related AEs of special interest5131
Serious adverse events of special interest0000
SecondaryPlasma Concentration of Atrasentan

Blood samples were collected for the measurement of plasma concentrations of atrasentan.

Time frame:
Treatment Period 1: Pre-dose on Weeks 2, 6 and 12; Treatment Period 2: Pre-dose on Weeks 2, 6, 12 and 24
Reported as:
Median · ng/mL
Plasma Concentration of Atrasentan
ng/mLAtrasentan Period 1Atrasentan Period 2
Week 2 - Predose1.07 (0.866 to 1.81)1.13 (0.579 to 1.53)
Week 6 - Predose1.41 (1.08 to 2.39)1.26 (0.855 to 1.47)
Week 12 - Predose1.28 (0.846 to 2.19)1.17 (0.633 to 1.61)
Week 24 - Predose—1.06 (0.547 to 1.38)

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days, up to a maximum duration of 60 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Total0/54 (0%)0/54 (0%)1/54 (1.9%)
Treatment Period: Atrasentan0/27 (0%)0/27 (0%)11/27 (40.7%)
Treatment Period 1: Placebo0/27 (0%)0/27 (0%)8/27 (29.6%)
Treatment Period 1 Total0/54 (0%)0/54 (0%)19/54 (35.2%)
Washout Period: Atrasentan0/27 (0%)0/27 (0%)7/27 (25.9%)
Washout Period: Placebo0/27 (0%)0/27 (0%)3/27 (11.1%)
Washout Period Total0/54 (0%)0/54 (0%)10/54 (18.5%)
Treatment Period 2: Placebo0/27 (0%)0/27 (0%)13/27 (48.1%)
Treatment Period 2: Atrasentan0/27 (0%)1/27 (3.7%)5/27 (18.5%)
Treatment Period 2 Total0/54 (0%)1/54 (1.9%)18/54 (33.3%)
Follow-up Period: Placebo0/27 (0%)0/27 (0%)0/27 (0%)
Follow-up Period: Atrasentan0/27 (0%)0/27 (0%)0/27 (0%)
Follow-up Period: Total0/54 (0%)0/54 (0%)0/54 (0%)
Most frequent serious events
Most frequent serious events
EventRun-in TotalTreatment Period: AtrasentanTreatment Period 1: PlaceboTreatment Period 1 TotalWashout Period: AtrasentanWashout Period: PlaceboWashout Period TotalTreatment Period 2: PlaceboTreatment Period 2: AtrasentanTreatment Period 2 TotalFollow-up Period: PlaceboFollow-up Period: AtrasentanFollow-up Period: Total
Cytomegalovirus infectionInfections and infestations0/540/270/270/540/270/270/540/271/271/540/270/270/54
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRun-in TotalTreatment Period: AtrasentanTreatment Period 1: PlaceboTreatment Period 1 TotalWashout Period: AtrasentanWashout Period: PlaceboWashout Period TotalTreatment Period 2: PlaceboTreatment Period 2: AtrasentanTreatment Period 2 TotalFollow-up Period: PlaceboFollow-up Period: AtrasentanFollow-up Period: Total
Upper respiratory tract infectionInfections and infestations0/544/270/274/543/271/274/543/272/275/540/270/270/54
Fluid retentionMetabolism and nutrition disorders0/543/270/273/540/270/270/543/271/274/540/270/270/54
HypotensionVascular disorders0/541/271/272/541/270/271/543/271/274/540/270/270/54
GastroenteritisInfections and infestations0/541/271/272/540/271/271/542/270/272/540/270/270/54
InfluenzaInfections and infestations0/542/271/273/540/270/270/541/270/271/540/270/270/54
NasopharyngitisInfections and infestations0/540/272/272/541/270/271/542/271/273/540/270/270/54
Viral infectionInfections and infestations0/542/270/272/540/270/270/540/270/270/540/270/270/54
Back painMusculoskeletal and connective tissue disorders0/540/272/272/542/270/272/540/272/272/540/270/270/54
DizzinessNervous system disorders0/542/270/272/540/270/270/540/271/271/540/270/270/54
HeadacheNervous system disorders0/540/271/271/540/270/270/542/272/274/540/270/270/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sequence Atrasentan/PlaceboSequence Placebo/AtrasentanTotal
<=18 years000
Between 18 and 65 years232649
>=65 years415
Age, Continuous
Age, Continuous(years)Sequence Atrasentan/PlaceboSequence Placebo/AtrasentanTotal
Mean52.2 ± 11.4343.2 ± 10.6647.7 ± 11.85
Sex: Female, Male
Sex: Female, Male(Participants)Sequence Atrasentan/PlaceboSequence Placebo/AtrasentanTotal
Female121123
Male151631
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence Atrasentan/PlaceboSequence Placebo/AtrasentanTotal
Asian10515
White152035
Multiple123
Not reported101
08

Study locations

30 sites
  • University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic
    Birmingham, Alabama 35233, United States
  • Fides Clinical Research
    Atlanta, Georgia 30342, United States
  • NANI Research
    Oak Brook, Illinois 60523, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • University of North Carolina at Chapel Hill - Nephrology and Hypertension
    Chapel Hill, North Carolina 27599, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The St. George Hospital
    Kogarah, New South Wales 2217, Australia
  • Prince of Wales Hospital
    Sydney, New South Wales 2031, Australia
  • Monash Health- Monash Medical Centre
    Melbourne, Victoria 3168, Australia
  • Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • NUPEC Cardio
    Belo Horizonte, Minas Gerais 30220-140, Brazil
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
  • Universidade Federal de Sao Paulo
    São Paulo, São Paulo 04038-002, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da USP
    São Paulo, São Paulo 05403-000, Brazil
  • Hopsital Sultanah Aminah Johor Bharu (HSAJB) - Bangunan Bakawali Heodialysis Centre
    Johor Bahru, Johor Darul Takzim 80100, Malaysia
  • Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
    Cheras, Kuala Lumpur 56000, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, Kuala Lumpur 59100, Malaysia
  • Hospital Raja Permaisuri Bainun (HRPB)
    Ipoh, Perak 30450, Malaysia
  • Dong-A University Medical Center (Dong-A University Hospital)
    Busan, Busan 49201, South Korea
  • Soon Chun Hyang Central Medical Center (SCHMC) - Soon Chun Hyang University Hospital
    Cheonan, Chungnam-Do 31151, South Korea
  • Hallym University Sacred Heart Hospital
    Anyang-si, Gyeonggi-do 14068, South Korea
  • Chung-Ang University College
    Seoul, Seoul 06973, South Korea
  • Hospital Torrecardenas
    Almería, 04009, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital del Vall d´Hebron
    Barcelona, 08035, Spain
  • Hospital Ribera Polusa
    Lugo, 27004, Spain
  • Hospital Universitario De Getafe (HUG)
    Madrid, 28009, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Virgen Macarena
    Seville, 41009, Spain
  • Hospital Clinico Universitario
    Valencia, 46010, Spain
09

References and documents

Publications

  • Heerspink HJL, Noronha IL, Gorriz JL, Lim SK, Kotwal SS, Kirsztajn GM, Barros Neto J, Ryan J, Fu MS, Kim SG, Barratt J, Brahmbhatt Y, Housler GJ, Jiao R, Dahlke M, Lodha A, Mottl AK; Atrasentan and Sodium Glucose Cotransporter-2 Inhibitor Efficacy and Safety Trial (ASSIST) Investigator Group. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001076. Online ahead of print. PubMed 41904616 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2025, 23 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Apr 28, 2023
StartActual
Jul 20, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Oct 29, 2025
Results first posted
Jul 20, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05834738
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
Jul 20, 2023
Primary completion
Jun 30, 2025
Completion
Oct 29, 2025
Results posted
Jul 20, 2026
Last update
Jul 20, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion